Page 36 - 2022_03-Haematologica-web

T. Kaburagi et al.
myelomonocytic leukemia, myelodysplas- tic syndromes and acute myeloid leukemia. Nat Genet. 2003;34(2):148-150.
40. Tartaglia M, Martinelli S, Cazzaniga G, et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogen- esis in childhood acute leukemia. Blood. 2004;104(2):307-13.
41.Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the noonan syn- drome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myel- ogenous leukemia. Cancer Res. 2004;64(24): 8816-8820.
42. Martinelli S, Stellacci E, Pannone L, et al. Molecular diversity and associated pheno- typic spectrum of germline CBL mutations. Hum Mutat. 2015;36(8):787-796.
43. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682-4689.
44. Shiba N, Ohki K, Kobayashi T, et al. High
PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid
leukaemia correlated to FLT3-ITD, KMT2A- PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial. Br J Haematol. 2016;172(4):581-591.
45. Goemans BF, Zwaan CM, Martinelli S, et al. Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia. Br J Haematol. 2005;130(5):801-803
46.Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129 (4):424-447.
47. Yamato G, Shiba N, Yoshida K, et al. RUNX1 mutations in pediatric acute myeloid leukemia are associated with dis- tinct genetic features and an inferior progno- sis. Blood. 2018;131(20):2266-2270.
48. Barjesteh van Waalwijk van Doorn- Khosrovani S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study
of 319 de novo AML patients. Blood.
2003;101(3):837-845.
49. Goemans BF, Zwaan CM, Miller M, et al.
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005;19(9): 1536-1542.
50. Kales SC, Ryan PE, Nau MM, Lipkowitz S. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res. 2010;70(12):4789-4794.
51. Locatelli F, Niemeyer CM. How I treat juve- nile myelomonocytic leukemia. Blood. 2015;125(7):1083-1090.
52. Niemeyer CM, Flotho C. Juvenile myelomonocytic leukemia: who's the driver at the wheel? Blood. 2019;133(10):1060- 1070.
53. Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloprolifera- tive disorders of childhood: a study of 167 patients. Blood. 1999;93(2):459-466.
54. Niemeyer CM. RAS diseases in children. Haematologica. 2014;99(11):1653-1662.
592
haematologica | 2022; 107(3)